title: Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.
abstract: BACKGROUND
  We evaluated the safety and efficacy of etanercept, a soluble tumor necrosis factor receptor (p75):Fc fusion protein, in children with polyarticular juvenile rheumatoid arthritis who did not tolerate or had an inadequate response to methotrexate.
  
  
  METHODS
  Patients 4 to 17 years old received 0.4 mg of etanercept per kilogram of body weight subcutaneously twice weekly for up to three months in the initial, open-label part of a multicenter trial. Those who responded to treatment then entered a double-blind study and were randomly assigned to receive either placebo or etanercept for four months or until a flare of the disease occurred. A response was defined as an improvement of 30 percent or more in at least three of six indicators of disease activity, with no more than one indicator worsening by more than 30 percent.
  
  
  RESULTS
  At the end of the open-label study, 51 of the 69 patients (74 percent) had had responses to etanercept treatment. In the double-blind study, 21 of the 26 patients who received placebo (81 percent) withdrew because of disease flare, as compared with 7 of the 25 patients who received etanercept (28 percent) (P=0.003). The median time to disease flare with placebo was 28 days, as compared with more than 116 days with etanercept (P<0.001). In the double-blind study, there were no significant differences between the two treatment groups in the frequency of adverse events.
  
  
  CONCLUSIONS
  Treatment with etanercept leads to significant improvement in patients with active polyarticular juvenile rheumatoid arthritis. Etanercept is well tolerated by pediatric patients.
authors.affiliation: Children's Hospital Medical Center, Cincinnati, OH 45229-3039, USA.
authors.forename: D J
authors.initials: DJ
authors.lastname: Lovell
authors.forename: E H
authors.initials: EH
authors.lastname: Giannini
authors.forename: A
authors.initials: A
authors.lastname: Reiff
authors.forename: G D
authors.initials: GD
authors.lastname: Cawkwell
authors.forename: E D
authors.initials: ED
authors.lastname: Silverman
authors.forename: J J
authors.initials: JJ
authors.lastname: Nocton
authors.forename: L D
authors.initials: LD
authors.lastname: Stein
authors.forename: A
authors.initials: A
authors.lastname: Gedalia
authors.forename: N T
authors.initials: NT
authors.lastname: Ilowite
authors.forename: C A
authors.initials: CA
authors.lastname: Wallace
authors.forename: J
authors.initials: J
authors.lastname: Whitmore
authors.forename: B K
authors.initials: BK
authors.lastname: Finck
mesh_terms: D000203:Activities of Daily Living; D000293:Adolescent; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001171:Arthritis, Juvenile / Q000188:drug therapy* / Q000503:physiopathology; D002648:Child; D002675:Child, Preschool; D004311:Double-Blind Method; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000032:analysis / Q000627:therapeutic use*; D008297:Male; D018124:Receptors, Tumor Necrosis Factor / Q000032:analysis / Q000627:therapeutic use*
chemical_list: D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept